Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2014-04-15
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 38
- Registration Number
- NCT00482846
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 89
- Registration Number
- NCT00477971
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT00477750
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT00477815
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Sally Arai
- Target Recruit Count
- 22
- Registration Number
- NCT00477035
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 93
- Registration Number
- NCT00472056
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00469209
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧Hereford Hospitals, Hereford, United Kingdom
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
Vaccine Therapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019097
- Locations
- 🇺🇸
Arkansas Cancer Research Center, Little Rock, Arkansas, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Medicine Branch, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.